Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · IEX Real-Time Price · USD
0.969
+0.003 (0.31%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Chemomab Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for CMMB stock have an average target of 5.67, with a low estimate of 4.00 and a high estimate of 7.00. The average target predicts an increase of 485.14% from the current stock price of 0.97.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 13, 2024.
Analyst Ratings
The average analyst rating for CMMB stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +312.80% | May 13, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +519.20% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Mar 8, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +622.39% | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +622.39% | Oct 6, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.03
from -2.06
EPS Next Year
-0.04
from -0.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | n/a |
| Avg | n/a | n/a | n/a | n/a | n/a |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.03 | -0.04 | -0.08 | -0.05 | -0.04 |
| Avg | -0.03 | -0.04 | -0.08 | -0.05 | -0.05 |
| Low | -0.03 | -0.04 | -0.08 | -0.05 | -0.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.